Summary of COVID-19 ebselen studies

1. Treggiari et al., A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients

25 patient ebselen late treatment RCT: 125% higher mortality (p=0.62) and 13% worse recovery (p=0.78).
RCT 25 severe COVID-19 patients showing no significant differences with SPI-1005 (ebselen).
Jun 2026, NCT04483973, https://clinicaltrials.gov/study/NCT04483973, https://c19p.org/treggiari2

2. Treggiari et al., A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients

31 patient ebselen late treatment RCT: 141% higher mortality (p=1) and 21% worse recovery (p=0.67).
RCT 31 moderate COVID-19 patients showing no significant differences with SPI-1005 (ebselen).
Jun 2026, NCT04484025, https://clinicaltrials.gov/study/NCT04484025, https://c19p.org/treggiari